Skip to content

The Effect of Ultrasound-Guided Superficial vs. Deep Paravertebral Nerve Block at the Superior Costotransverse Ligament on Hemodynamics During Induction in Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial

The Effect of Ultrasound-Guided Superficial vs. Deep Paravertebral Nerve Block at the Superior Costotransverse Ligament on Hemodynamics During Induction in Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095907
Enrollment
Unknown
Registered
2025-01-15
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative hypotension

Interventions

SCTL Deep Surface Blocking Group (T Group):30 minutes before surgery, the SCTL deep surface block is completed under ultrasound guidance in the preoperative room
SCTL Superficial Cervical Trigger Point Inhibition Group (S Group):Superficial SCTL block under ultrasound guidance was completed in the pre-anesthesia room 30min before operation

Sponsors

NanJing First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Subjects who were scheduled to undergo double-hole thoracoscopic lobectomy were 18-65 years old, ASA grade I to III, BMI 18-30 kg/m^2.

Exclusion criteria

Exclusion criteria: 1.Severe hypertension (systolic blood pressure >= 180 mmHg or diastolic blood pressure >= 110 mmHg); 2.MAP < 70mmHg before anesthesia induction; 3.emergency surgery; 4.severe cardiovascular disease (history of brain or thoracic/abdominal aortic aneurysm); 5.congestive heart failure, i.e., New York Heart Association classification III or IV; 6.untreated or unstable ischemic heart disease; 7.history of severe aortic or mitral valve disease; 8.pregnant or lactating women; 9.abnormal coagulation function; 10.sepsis, septicemia, or infection at the puncture site; 11.allergy to any of the drugs involved in the trial; 12.neurological or spinal disorders (deformity or trauma, surgical history), abnormal skin sensation in the thoracic and back; 13.difficulty in airway management; 14.or determined by the investigator to be ineligible.

Design outcomes

Primary

MeasureTime frame
Incidence of hypotension;

Secondary

MeasureTime frame
Incidence of severe hypotension;VAS scores at rest and exercise (cough) 4 and 24 hours after surgery;Use of vasoactive drugs during induction;Intraoperative use of propofol and remifentanil;Anesthesia time, intraoperative intravenous infusion volume, intraoperative urine volume, intraoperative blood loss, extubation time;Puncture related adverse events;Analgesic pump usage within 24 hours;QOR-40 score 24 hours after surgery;The patient experienced puncture related complications within 72 hours after surgery;Satisfaction survey 72 hours after operation;

Countries

China

Contacts

Public ContactWang Xiaoliang

NanJing First Hospital

wxl145381@njmu.edu.cn+86 25 52271030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026